[go: up one dir, main page]

AR034343A1 - Combinaciones farmaceuticas - Google Patents

Combinaciones farmaceuticas

Info

Publication number
AR034343A1
AR034343A1 ARP020101955A ARP020101955A AR034343A1 AR 034343 A1 AR034343 A1 AR 034343A1 AR P020101955 A ARP020101955 A AR P020101955A AR P020101955 A ARP020101955 A AR P020101955A AR 034343 A1 AR034343 A1 AR 034343A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical combinations
pharmaceutically acceptable
acceptable derivative
combinations
thrombotic
Prior art date
Application number
ARP020101955A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR034343A1 publication Critical patent/AR034343A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente provee combinaciones farmacéuticas y su utilización en la terapia anti-trombótica. Las combinaciones comprenden un compuesto de la fórmula (1) o su derivado farmacéuticamente aceptable y otro agente anti-trombótico o su derivado farmacéuticamente aceptable.
ARP020101955A 2001-05-31 2002-05-24 Combinaciones farmaceuticas AR034343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
AR034343A1 true AR034343A1 (es) 2004-02-18

Family

ID=20284321

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101955A AR034343A1 (es) 2001-05-31 2002-05-24 Combinaciones farmaceuticas

Country Status (24)

Country Link
US (2) US20040146498A1 (es)
EP (1) EP1397139A1 (es)
JP (1) JP2004532869A (es)
KR (1) KR20040003029A (es)
CN (1) CN100352442C (es)
AR (1) AR034343A1 (es)
AU (1) AU2002305952B2 (es)
BR (1) BR0210034A (es)
CA (1) CA2447648A1 (es)
CO (1) CO5550445A2 (es)
CZ (1) CZ20033246A3 (es)
EE (1) EE200300589A (es)
HU (1) HUP0400069A3 (es)
IL (1) IL158780A0 (es)
IS (1) IS7051A (es)
MX (1) MXPA03010761A (es)
NO (1) NO20035315D0 (es)
PL (1) PL366510A1 (es)
RU (1) RU2331422C2 (es)
SE (1) SE0101932D0 (es)
SK (1) SK14732003A3 (es)
TW (1) TWI232751B (es)
WO (1) WO2002096428A1 (es)
ZA (1) ZA200308780B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
JP2004346067A (ja) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp 抗血栓薬の治療可能時間を延長するための薬剤
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005040174A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
WO2006045756A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
WO2008054795A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
IN2012DN04412A (es) * 2009-11-09 2015-08-07 Alexion Pharmaceuticals Inc
JP2013512886A (ja) * 2009-12-03 2013-04-18 アストラゼネカ アクチボラグ 血小板の凝集阻害剤トリアゾロ［４，５−ｄ］ピリミジン共結晶
CA2785487C (en) 2009-12-23 2017-11-28 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
RU2013154741A (ru) 2011-06-01 2015-07-20 Астразенека Аб Новый сокристалл тикагрелора
US20160120869A1 (en) * 2013-05-29 2016-05-05 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
WO2016116942A1 (en) * 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
RU2707959C2 (ru) * 2015-01-27 2019-12-03 Астразенека Аб Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе
CN106204544B (zh) * 2016-06-29 2019-04-05 南京中观软件技术有限公司 一种自动提取图像中标志点位置及轮廓的方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
SK283206B6 (sk) * 1995-07-11 2003-03-04 Astra Pharmaceuticals Ltd. Inhibítory agregácie krvných doštičiek, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
JP2002538226A (ja) * 1999-03-11 2002-11-12 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤およびアスピリン、組織プラスミノーゲンアクチベータ（ＴＰＡ）、ＧＰＩＩｂ／ＩＩＩａ拮抗剤、低分子量ヘパリンまたはヘパリンの組合せ使用による血栓症の治療
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations

Also Published As

Publication number Publication date
CZ20033246A3 (cs) 2004-02-18
PL366510A1 (en) 2005-02-07
AU2002305952B2 (en) 2007-08-09
CO5550445A2 (es) 2005-08-31
US20060189584A1 (en) 2006-08-24
ZA200308780B (en) 2005-02-11
KR20040003029A (ko) 2004-01-07
CN1512885A (zh) 2004-07-14
TWI232751B (en) 2005-05-21
IL158780A0 (en) 2004-05-12
RU2331422C2 (ru) 2008-08-20
IS7051A (is) 2003-11-26
NO20035315D0 (no) 2003-11-28
EP1397139A1 (en) 2004-03-17
SE0101932D0 (sv) 2001-05-31
CN100352442C (zh) 2007-12-05
BR0210034A (pt) 2004-08-10
WO2002096428A1 (en) 2002-12-05
US20040146498A1 (en) 2004-07-29
JP2004532869A (ja) 2004-10-28
CA2447648A1 (en) 2002-12-05
EE200300589A (et) 2004-02-16
MXPA03010761A (es) 2004-03-02
RU2003133216A (ru) 2005-04-20
HUP0400069A3 (en) 2006-02-28
SK14732003A3 (sk) 2004-05-04
HUP0400069A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
AR034343A1 (es) Combinaciones farmaceuticas
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
GB0005251D0 (en) Therapeutic compounds
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
PL374831A1 (pl) Zmodyfikowane proleki 2' i 3'-nukleozydowe do leczenia zakażeń Flaviviridae
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
GEP20063799B (en) Tropane derivatives useful in therapy
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
BR0313747A (pt) Inibidores de transcriptase reversa de não-nucleosìdeo
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
EE05020B1 (et) Glburiidi ravimkoostis
NO20014314L (no) Blandinger og metoder for behandling av stafylokokkisk infeksjon
SI1764111T1 (sl) AntidisritmiŽŤna sredstva za vaginalno dajanje za zdravljenje materniŽŤne disritmije
SV2002000235A (es) Composiciones farmaceuticas que comprenden valdecoxib
NO20024076D0 (no) Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer
SE0003476D0 (sv) Compounds
ITMI20010957A0 (it) Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche

Legal Events

Date Code Title Description
FA Abandonment or withdrawal